Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by FineMark National Bank & Trust

FineMark National Bank & Trust boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 10.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,702 shares of the medical research company’s stock after purchasing an additional 452 shares during the quarter. FineMark National Bank & Trust’s holdings in Thermo Fisher Scientific were worth $3,137,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Patriot Financial Group Insurance Agency LLC increased its stake in Thermo Fisher Scientific by 1.9% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 799 shares of the medical research company’s stock valued at $457,000 after purchasing an additional 15 shares during the last quarter. Karp Capital Management Corp grew its position in Thermo Fisher Scientific by 0.5% during the fourth quarter. Karp Capital Management Corp now owns 3,195 shares of the medical research company’s stock valued at $2,132,000 after acquiring an additional 17 shares during the period. Archer Investment Corp grew its position in Thermo Fisher Scientific by 1.3% during the fourth quarter. Archer Investment Corp now owns 1,317 shares of the medical research company’s stock valued at $879,000 after acquiring an additional 17 shares during the period. Deseret Mutual Benefit Administrators grew its position in Thermo Fisher Scientific by 2.7% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 647 shares of the medical research company’s stock valued at $432,000 after acquiring an additional 17 shares during the period. Finally, Mechanics Bank Trust Department grew its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Mechanics Bank Trust Department now owns 1,963 shares of the medical research company’s stock valued at $1,310,000 after acquiring an additional 18 shares during the period. Hedge funds and other institutional investors own 87.48% of the company’s stock.

Several equities research analysts have recently weighed in on TMO shares. BTIG Research reaffirmed a “buy” rating and issued a $718.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, February 3rd. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $609.00 target price for the company. in a research report on Monday, January 24th. Wells Fargo & Company cut Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $605.00 to $525.00 in a research note on Monday, April 25th. Barclays initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, January 26th. They issued an “overweight” rating and a $700.00 price target on the stock. Finally, StockNews.com initiated coverage on Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus target price of $647.00.

TMO stock traded up $1.12 on Monday, reaching $556.27. The company’s stock had a trading volume of 6,833 shares, compared to its average volume of 1,630,056. Thermo Fisher Scientific Inc. has a 52 week low of $438.72 and a 52 week high of $672.34. The company has a market capitalization of $217.76 billion, a P/E ratio of 28.94, a price-to-earnings-growth ratio of 1.87 and a beta of 0.83. The firm has a fifty day moving average of $565.30 and a two-hundred day moving average of $589.70. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.56 and a quick ratio of 1.10.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last issued its quarterly earnings data on Thursday, April 28th. The medical research company reported $7.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.20 by $1.05. The business had revenue of $11.82 billion during the quarter, compared to analyst estimates of $10.66 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period in the prior year, the company posted $7.21 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 22.69 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 15th. Shareholders of record on Wednesday, June 15th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date is Tuesday, June 14th. Thermo Fisher Scientific’s payout ratio is currently 6.26%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $545.60, for a total transaction of $5,456,000.00. Following the completion of the transaction, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at approximately $100,048,308.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 2,181 shares of the firm’s stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $562.46, for a total value of $1,226,725.26. Following the sale, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at $103,139,977.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,381 shares of company stock valued at $6,791,597. 0.43% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.